 Cortexyme Inc NASDAQ: CRTX has presented additional data from its Phase 23 GAIN Trial at the Clinical Trials on Alzheimers Disease Conference. The 643-participant 48-week GAIN Trial failed to meet statistical significance on its co-primary cognitive and functional endpoints in the overall cohort. 